InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

Current share price for LDX : $0.094 0.005 (5.05%)+

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$89 FebriDx Commercial Traction Across Priority US Accounts 21 Jul 2026 12:08PM $0.078 $0.094 risen by 20.51%
$89 Q4 FY26 Results Release Date and Webinar Invitation 20 Jul 2026 11:01AM $0.083 $0.094 risen by 13.25%
$89 Investor Information Sessions 20 Jul 2026 10:50AM $0.083 $0.094 risen by 13.25%
$89 Notification of cessation of securities - LDX 14 Jul 2026 1:06PM $0.087 $0.094 risen by 8.05%
$89 Closure of A$5M Loan Facility with Major Shareholders 2 Jul 2026 2:27PM $0.105 $0.094 fallen by 10.48%
$89 Lumos Receives Research & Development Tax Rebate 29 Jun 2026 9:54AM $0.115 $0.094 fallen by 18.26%
$89 Change of Director's Interest Notice - SL 25 Jun 2026 11:48AM $0.105 $0.094 fallen by 10.48%
$89 Application for quotation of securities - LDX 22 Jun 2026 12:12PM $0.115 $0.094 fallen by 18.26%
$89 Change of Director's Interest Notice - CR 19 Jun 2026 9:13AM $0.115 $0.094 fallen by 18.26%
$89 Investor Presentation - FebriDx US Commercial Update 11 Jun 2026 9:58AM $0.105 $0.094 fallen by 10.48%
$89 Change of Director's Interest Notice - DW 5 Jun 2026 2:51PM $0.100 $0.094 fallen by 6%
$89 FebriDx US Commercial Update Webinar Invitation 4 Jun 2026 11:23AM $0.105 $0.094 fallen by 10.48%
$89 Application for quotation of securities - LDX 20 May 2026 1:24PM $0.130 $0.094 fallen by 27.69%
$89 Section 708A Cleansing Statement 20 May 2026 1:24PM $0.130 $0.094 fallen by 27.69%
$89 FebriDx U.S. Rollout and Reimbursement Update - Amended 18 May 2026 11:42AM $0.125 $0.094 fallen by 24.80%
$89 FebriDx U.S. Rollout and Reimbursement Update 18 May 2026 9:49AM $0.125 $0.094 fallen by 24.80%
$89 FebriDx Paediatric Study Enrolment Milestone Achieved 14 May 2026 9:37AM $0.140 $0.094 fallen by 32.86%
$89 Lumos receives US$0.5m CLIA waiver milestone payment 7 May 2026 2:02PM $0.155 $0.094 fallen by 39.35%
$89 Change of Director's Interest Notice - CR 1 May 2026 11:16AM $0.168 $0.094 fallen by 43.88%
$89 Change of Director's Interest Notice - SL 1 May 2026 11:16AM $0.168 $0.094 fallen by 43.88%
$89 Notification regarding unquoted securities - LDX 1 May 2026 11:11AM $0.168 $0.094 fallen by 43.88%
$89 Notification regarding unquoted securities - LDX 1 May 2026 11:10AM $0.165 $0.094 fallen by 43.03%
$89 Application for quotation of securities - LDX 1 May 2026 11:08AM $0.165 $0.094 fallen by 43.03%
$89 Results of Share Purchase Plan 1 May 2026 11:04AM $0.165 $0.094 fallen by 43.03%
$89 Change of Director's Interest Notice - SL 30 Apr 2026 4:23PM $0.165 $0.094 fallen by 43.03%

1 - 25 of 536 results

Page 1 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.